About us
Founded in 2019, Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics) is a biotechnology company focused on the research, development and commercialization of cell therapies for the treatment of solid tumors. Leveraging our proprietary DeepTIL™ Cell Enrichment and Expansion Platform, NovaGMP™ Non-Viral Gene-Modification Platform, and RiverTIL™ In Vivo TIL Platform, we innovate at the source to enhance product efficacy and safety, and significantly reduce production and overall treatment costs to improve TIL therapy accessibility.
Focused on high-incidence tumors and hard-to-treat tumors, we have developed a pipeline of first-in-class and best-in-class autologous natural and gene-modified TIL therapies, covering adjuvant early treatment to later-line advanced therapy across multiple disease stages and treatment settings.
GC101, is the world's first TIL therapy that does not require high-intensity lymphodepletion chemotherapy or the use of IL-2administration. Expected to be China's first approved TIL therapy, it provides sustained clinical benefits to melanoma, NSCLC and other patients who have failed multiple lines of treatment. GC101 registrational Phase II clinical data results have been included in the latest breakthrough abstract by the American Society of Clinical Oncology (ASCO).
GC203, is the world's first non-viral gene-modified TIL therapy. It has obtained NMPA implied approval for refractory solid tumors such as ovarian cancer and pancreatic cancer. It has already demonstrated favorable efficacy and safety in advanced ovarian cancer patients who have failed multiple lines of treatment.
We are launching the world's first in vivo TIL platform. Designed to enable direct in vivo expansion, this platform has demonstrated great potential to transform a personalized treatment into a nearly off-the-shelf cell therapy capable of engaging patients much earlier in their treatment process, significantly reducing production costs and enhancing the accessibility of TIL therapy.
Additionally, Juncell Therapeutics co-drafted China's first TIL group standard and has already built commercial-scale TIL production facilities in China. In February 2026, we obtained China's first Drug Production License for TIL therapy.
In terms of financing, we have completed multiple rounds of financing totaling nearly RMB800 million, with continuous support from well-known domestic biopharmaceutical funds such as Kaitai Capital, Oriza Seed, Furong Capital, YuanBio Venture Capital and GZHP Biomedical Industry Investment Fund Management. As the clinical advancement of its core pipeline progresses, Juncell Therapeutics will play an important role in the global cancer treatment field, developing curative and affordable cell therapies to benefit a wide population of patients with solid tumors.
-
Team
Core team members have over 10 years of successful R&D experience in cell therapies.
-
Facilities
The 16,000+ m² Intelligent TIL Manufacturing Facility, featuring large-scale designed production capacity, high construction standards and intelligent facilities.
-
Financing
Multiple rounds of financing totaling nearly RMB800 million.
-
Honors
Shanghai Model Collective, Shanghai Labor Day Medal，Funded by National and Shanghai Municipal Key R&D Programs for Disruptive Innovation.
Founder , CEO & CTO
Dr. Huajun Jin
☛ National Special Subsidy Expert, Shanghai Leading Talent, Outstanding Tech Leaders, Forbes China Pioneer Innovator
☛ 20+ years of cross-disciplinary experience across industrial, academic, research and medical fields, especially in the development of biological therapies in oncotherapy
☛ Led the development of a series of world-first CAR-T and TIL therapies
☛ Presided over 15 national or provincial/municipal-level research projects
☛ Applied for more than 200 invention patents (including 56 granted domestic patents and 43 granted PCT patents)
☛ Published 23 SCI papers as the first author or corresponding author
Platform
☛ The 16,000+ m² Intelligent TIL Manufacturing Facility, featuring large-scale designed production capacity, high construction standards and intelligent facilities.
☛ 2,000㎡ GMP production workshops and quality control laboratories.
.jpg)
.jpg)
.jpg)
.jpg)
Milestones
-
2019☛ Our Company was established.
-
2020
☛ We completed the construction of R&D laboratory and office in
Shanghai.
-
2020
☛ We completed the pre-clinical study of TIL.
-
2020
☛ We completed our Series Pre-A Financing.
-
2021
☛ The IIT was commenced for GC101.
-
2021
☛ We completed our Series A and Series A+ Financings.
-
2022
☛ We completed the pre-clinical study for GC203.
-
2022
☛ We obtained NMPA IND approval for the clinical trial for GC101.
-
2022
☛ We commenced the Phase I clinical trial for GC101.
-
2022
☛ The IIT was commenced for GC203.
-
2022
☛ We completed our Series A++ Financing.
-
2024
☛ We obtained the NMPA IND approval to commence the Phase I clinical trial for GC203.
-
2024
☛ We commenced the Phase I clinical trial for GC203.
-
2024
☛ We commenced the Phase II clinical trial for GC101 for melanoma.
-
2024
☛ Our TIL cell manufacturing site in Shanghai commenced operation.
-
2024
☛ We commenced the Phase Ib/II clinical trial for GC101 for NSCLC.
-
2024
☛ We completed our Series B Financing.
-
2025
☛ The first patient was enrolled into the clinical trial group of the Phase II clinical trial for GC101 for melanoma.
-
2025
☛ We obtained NMPA IND approval for the Phase II clinical trial for GC101 in combination with a PD-1 antibody in advanced malignant solid tumors.
-
2025
☛ We achieved the target enrolment number of patients in the Phase II clinical trial for GC101 for melanoma.
-
2025
☛ We completed our Series B+ and Series C Financings.
-
2026
☛ We obtained the Drug Production License, which is the first manufacturing certificate of its kind for TIL therapies in China.
-
2026
☛ Our registrational Phase II clinical trial of GC101 for advanced melanoma met its primary endpoint. It was accepted as a late-breaking abstract and presented orally at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.
Culture
Our Mission
Rebuild Cells, Rescue Lives
Our Vision
Make miracles happen, Make miracles often.
Our Values
Concentration, Innovation, Inclusion, Collaboration
Honors
-
The Top 50 Most Innovative Bio-pharmaceutical Enterprises in China
-
The Annual Best Bio-pharmaceutical Enterprises
-
The Annual Best-growing Innovative Bio-Techs
-
10th China Innovation and Entrepreneurship Competition - National Finals
-
National High-Tech Enterprise
-
.png)
Top 10 Most Promising Innovative Therapy Enterprises 2022 China Biopharmaceutical Industry Value Ranking
-
Winner of the 2022 National Disruptive Technology Innovation Competition
-
.jpg)
The Top 5 Annual Best Investment Potential Bio-Techs
-
Top 10 Most Promising Cell and Gene Therapy Enterprises — 2022 China Biopharmaceutical Industry Value Ranking
-
Future Industry Excellence Award — 2023 Global "Future Industry Star" Competition
-
Shanghai "Specialized, Refined, Differentiated, and Innovative" SME
-
2024 Shanghai Oriental Talent Leadership Program
-
Shanghai May Day Labor Award
-
Shanghai Model Collective
-
2025 FNS101 Annual Biotech Pioneer Award
-
2025 Front-runners TOP 100
-
National Disruptive Technology Entrepreneurship Star — Mercury Enterprise
-
The Top 50 Most Innovative Bio-pharmaceutical Enterprises in China
-
The Annual Best Bio-pharmaceutical Enterprises
-
The Annual Best-growing Innovative Bio-Techs
-
10th China Innovation and Entrepreneurship Competition - National Finals
-
National High-Tech Enterprise
-
Top 10 Most Promising Innovative Therapy Enterprises 2022 China Biopharmaceutical Industry Value Ranking
-
Winner of the 2022 National Disruptive Technology Innovation Competition
-
The Top 5 Annual Best Investment Potential Bio-Techs
-
Top 10 Most Promising Cell and Gene Therapy Enterprises — 2022 China Biopharmaceutical Industry Value Ranking
-
Future Industry Excellence Award — 2023 Global "Future Industry Star" Competition
-
Shanghai "Specialized, Refined, Differentiated, and Innovative" SME
-
2024 Shanghai Oriental Talent Leadership Program
-
Shanghai May Day Labor Award
-
Shanghai Model Collective
-
2025 FNS101 Annual Biotech Pioneer Award
-
2025 Front-runners TOP 100
-
National Disruptive Technology Entrepreneurship Star — Mercury Enterprise
-
The Top 50 Most Innovative Bio-pharmaceutical Enterprises in China
-
The Annual Best Bio-pharmaceutical Enterprises
-
The Annual Best-growing Innovative Bio-Techs
-
10th China Innovation and Entrepreneurship Competition - National Finals
-
National High-Tech Enterprise
-
Top 10 Most Promising Innovative Therapy Enterprises 2022 China Biopharmaceutical Industry Value Ranking
-
Winner of the 2022 National Disruptive Technology Innovation Competition
-
The Top 5 Annual Best Investment Potential Bio-Techs
-
Top 10 Most Promising Cell and Gene Therapy Enterprises — 2022 China Biopharmaceutical Industry Value Ranking
-
Future Industry Excellence Award — 2023 Global "Future Industry Star" Competition
-
Shanghai "Specialized, Refined, Differentiated, and Innovative" SME
-
2024 Shanghai Oriental Talent Leadership Program
-
Shanghai May Day Labor Award
-
Shanghai Model Collective
-
2025 FNS101 Annual Biotech Pioneer Award
-
2025 Front-runners TOP 100
-
National Disruptive Technology Entrepreneurship Star — Mercury Enterprise